Heme oxygenase-carbon monoxide-cGMP (HO-CO-cGMP) pathway has been reported to be involved in peripheral and spinal modulation of inflammatory pain. However, the involvement of this pathway in the modulation of acute painful stimulus in the absence of inflammation remains unknown. Thus, we evaluated the involvement of the HO-CO-cGMP pathway in nociception by means the of analgesia index (AI) in the tail flick test. Rats underwent surgery for implantation of unilateral guide cannula directed toward the lateral ventricle and after the recovery period (5-7 days) were subjected to the measures of baseline tail flick test. Animals were divided into groups to assess the effect of intracerebroventricular administration (i.c.v.) of the following compounds: ZnDPBG (HO inhibitor) or vehicle (Na 2 CO 3 ), heme-lysinate (substrate overload) or vehicle (L-lysine), or the selective inhibitor of soluble guanilate cyclase ODQ or vehicle (DMSO 1%) following the administration of heme-lysinate or vehicle. Heme overload increased AI, indicating an antinociceptive role of the pathway. This response was attenuated by i.c.v. pretreatment with the HO inhibitor ZnDPBG. In addition, this effect was dependent on cGMP activity, since the pretreatment with ODQ blocked the increase in the AI. Because CO produces most of its actions via cGMP, these data strongly imply that CO is the HO product involved in the antinociceptive response. This modulation seems to be phasic rather than tonic, since i.c.v. treatment with ZnDPBG or ODQ did not alter the AI. Therefore, we provide evidence consistent with the notion that HO-CO-cGMP pathway plays a key phasic antinociceptive role modulating noninflammatory acute pain. 
Introduction
The pain sensation commonly refer to conscious experiences associated with tissue injury or disease and are also used to describe discomfort related to other unpleasant feelings (Perl, 2007) . The processing of nociceptive stimulus can be modulated in forebrain, in midbrain, and in spinal cord through mechanisms involving different neurotransmitters and neuromodulators (Casey, 1999) . Among them, carbon monoxide (CO) has been shown to play a role in peripheral and spinal modulation of inflammatory pain (Nascimento and Branco, 2007) , but no information is available as to its putative role in acute pain modulation in the absence of inflammation. CO has been recognized to act as a neurotransmitter or neuromodulator in the nervous system (Mancuso et al., 2010) . Moreover, CO has been shown to be a mediator of endotoxin fever in the central nervous system (Steiner et al., 1999; Steiner and Branco, 2000) . Most of CO's action has been reported to be dependent on the activation of soluble guanylate cyclase (sGC) activity and on subsequent increases the cellular levels of cyclic GMP (Maines, 1993 (Maines, , 1997 Morita et al., 1995) .
Endogenous CO arises from the cleavage of the heme molecule yielding equilomar amounts of biliverdin, free iron and CO, a process catalyzed by the enzyme heme oxygenase (HO) (Maines, 1997) . Three HO isoforms have been identified to date: HO-1, HO-2, and HO-3, among which the isoforms 1 and 2 are the best known Maines, 1997) . Both isoenzymes, one of them inducible (HO-1) and the other constitutive (HO-2), have been found in various tissues, including endothelial cells, smooth muscle and neural tissue (Dawson and Snyder, 1994; Maines, 1997; Johnson et al., 1999) .
Because the enzyme HO is widely distributed among the central nervous system (CNS) and central nociceptive transmission is an important step in pain perception and modulation (Millan, 1999) , we assessed the involvement of the HO-CO-cGMP pathway in nociception by means the of analgesia index (AI) in the tail flick test in rats. To this end, we investigated whether microinjection of zinc deuteroporphyrin 2,4-bis glycol (ZnDPBG, an HO inhibitor), heme-lysinate (substrate overload) or the selective inhibitor of soluble guanylate cyclase (ODQ) into the lateral ventricle in different groups of rats produces alterations on AI of the tail flick test.
Results
The results of the present study initially showed that the i. Fig. 3A ). 
Discussion
The present data are consistent with the notion that the HO-CO-cGMP pathway modulates nociception in the brain, playing an antinociceptive role. This conclusion is based on the fact that i.c.v. administration of the HO pathway-inducer heme-lysinate increased AI and that this effect could be attenuated by the i.c.v. pretreatment with ZnDPBG or with sGC inhibitor, ODQ. Moreover, CO seems to be the HO product responsible for this effect because it acts through a cGMPdependent way (Maines, 1997; Nascimento and Branco, 2007) . We also demonstrated that the i.c.v. microinjection of ZnDPBG (a competitive inhibitor of the HO) did not cause changes in the AI, indicating that HO-CO-cGMP pathway exhibits phasic but not tonic characteristics in the nociceptive modulation of acute painful stimuli in the absence of inflammation.
Since the beginning of the 1990s, a growing body of evidence has confirmed the physiological actions of the gaseous compound CO, which has been shown to be a vasoactive substance and to act as a neurotransmitter/ neuromodulator (Dawson and Snyder, 1994; Johnson et al., 1999) . HO is the enzyme responsible for CO biosynthesis and has been found to be expressed in the CNS of several species, including rats (Alam and Den, 1992; and humans (Maines et al., 1996) . Accordingly, evidence has accumulated that the HO-CO pathway plays an important role in the control of arterial blood pressure (Johnson et al., 1999) , in the mechanical hypernociception and in the formalin test (Nascimento and Branco, 2007) .
The HO enzyme inhibitor ZnDPBG prevents cleavage of the heme molecule and thus the production of endogenous biliverdin, free iron and carbon monoxide (Maines, 1997) . Direct intrathecal injection of ZnDPBG produced hypernociception, which was characterized by an increased flinching nociceptive response to the formalin test Branco, 2007, 2008) or mechanical hypersensitivity ). In addition, recent information (Nascimento and Branco, 2009) shows that administration of doses without any effect on ZnDPBG, when given alone, may promote the same hypernociceptive effect when administered intrathecally and locally. This suggests that the enzyme heme oxygenase modulates the inflammatory nociceptive response. These findings show that the activation of the HO system in the spinal cord can modulate the nociception in peripheral tissues (Nascimento and Branco, 2009 ). The present study adds to this scenario, demonstrating that heme overload using heme-lysinate has an antinociceptive effect in the absence of inflammation, evidenced by the increase in the AI in the tail flick test. Similar findings have been observed after heme-lysinate administered in the paw (Nascimento and Branco 2007) or given intrathecally (Nascimento and Branco 2008) , indicating that HO pathway plays an antinociceptive role at peripheral nervous system, spinal cord and brain. Furthermore, the HO pathway may involve not only the modulation of inflammatory mediator release or activity but also changes in nociceptors, fiber excitability and spinal sensitization.
The modulation of nociception by the activity of the HO-CO-cGMP pathway is due to increased intracellular cGMP levels because intrathecal treatment with heme-lysinate is blocked by pre-administration of methylene blue (inhibitor of sGC) at the same site. In addition, evidence shows that cGMP is capable of tonically modulating nociception associated with the inflammatory response because the administration of methylene blue (150 μg) caused hypernociception in the formalin test Branco, 2008, 2009) .
Our data also show that the administration of sGC inhibitor (ODQ) prior to administration of heme-lysinate blocked the antinociception observed in the tail flick test in rats. These results support the hypothesis that the antinociception obtained in our experiments is mediated by CO and related to increase of intracellular cGMP. Within this context, several studies have demonstrated that modulation of nociception can occur by altering the activity of intracellular cGMP (Meller and Gebhart, 1993; Duarte and Ferreira, 1992; Branco, 2007, 2008) . However, the change in intracellular levels of cGMP can result in pro-or antinociceptive effects, depending on the magnitude of the increase in cGMP as well as whether the drug is administered locally (in the peripheral nervous system or spinal cord). Thus, studies have shown that increased cGMP activity in the spinal cord inhibits the activity of spinal neurons, mainly nociceptive neurons of the dorsal horn in the spinal cord (Manjarrez et al., 2001, Pehl and Schmid, 1997; Hoheisel et al., 2000) . In contrast, Hoheisel et al. (2005) demonstrated that the supraspinal increase in the levels of cGMP promoted excitement in neurons located in the dorsal horn of the spinal cord, suggesting a probable pronociceptive effect. In our experiments, the increase of cGMP was promoted by activation of the HO-CO-cGMP pathway and slight increases in CO activated sGC (Burstyn et al., 1995) . Therefore supraspinal cGMP may have a dual effect; high levels of cGMP may have a pro-nociceptive effect or increase the activity of spinal nociceptive neurons (Hoheisel et al., 2005) . In contrast, lower-magnitude changes in supraspinal cGMP induce antinociceptive effects, as evidenced by the increase in AI after administration of heme-lysinate, which was blocked by the pretreatment with ODQ (inhibitor of sGC). It is possible that the modulation of nociception by increasing supraspinal cGMP occurs in regions that control the activity of the descending tracts of spinal neurons (Hoheisel et al., 2005) . Assuming that i.c.v. injection can affect all the cerebral ventricles (Yu et al., 1991) , localization of the supraspinal effect remains to be determined. Areas known to inhibit the activation nociceptive descending neurons, including the periaqueductal gray matter, amygdala and thalamus, may also be involved (Fields and Basbaum, 1999; Millan, 2002) . The most common isoforms of the heme oxygenase enzyme, HO-1 and HO-2, have wide distribution in the central nervous system . Among the areas that express HO, intense immunoreactivity can be observed in the hippocampal complex, including pyramidal neurons in CA1-CA3, neurons of the granular layer and some neurons in the dentate gyrus (Ewing et al., 1993 , Maines et al., 1996 . Recent work (Shih et al., 2008) using functional mapping techniques showed that the nociception induced by administration of formalin 5% intra-foot wide in rats promoted activation of different brain areas, including hippocampus. In fact, the involvement of the hippocampus in nociceptive modulation is widely described (Lico et al., 1974 , Khanna, 2007 and suggests that this structure is involved in the affectivemotivational component of pain (Lico et al., 1974 , Henke, 1982 . In addition, studies have correlated the activity of cGMP with functions performed by the hippocampal areas (Bon and Garthwaite, 2003, Hopper and Garthwaite, 2006) . Hippocampal areas have been shown to express high levels of HO isoenzymes, and CO has been suggested to be the main signaling molecule for sGC in this structure (Maines, 1997) . Moreover, the activity of cGMP in the hippocampus may be related to the activation of NMDA receptors (Garthwaite et al., 1995) , and the glutamatergic NMDA-type mediates different physiological functions, including nociception (Dubner, 2004 , Meller et al., 1996 , Morgan et al., 2009 .
Thus, our data show that activation of the HO-CO-cGMP pathway promotes antinociception, as assessed by tail flick test in rats. We speculate that the hippocampus is one of the areas involved in nociceptive modulation induced by increased cGMP formation, induced by CO carried on the heme molecule.
4.
Experimental procedures
Animals
Experiments were performed on male Wistar rats weighing 250-300 g obtained from the animal facility of the University of Sao Paulo, Ribeirao Preto, Brazil. The animals were housed in a room with controlled temperature (24 ± 1°C) and a 12-h light/ dark cycle (lights on at 06:00 h) with food and water ad libitum. All experimental procedures were approved by the Animal Use and Ethics Committee of the Ribeirao Preto, University of Sao Paulo (Process no. 07.1.997.53.4).
Surgery
During all surgical procedures, animals were submitted to anesthesia with ketamine and xylazine (75 and 10 mg/kg, respectively, administered intramuscularly). Animals designated for experiments involving intracerebroventricular (i.c.v.) injections were fixed in a stereotaxic frame and had a stainless steel guide cannula introduced into the right lateral cerebral ventricle (coordinates: 1.0 mm posterior, 1.6 mm lateral to midline and 3.2-3.7 mm ventral to the skull surface) (Paxinos and Watson, 1998) . Displacement of the meniscus in a water manometer ensured correct positioning of the cannula in the lateral ventricle. The cannulas were attached to the bone with stainless steel screws and acrylic cement. A tight-fitting stylet was kept inside the guide cannula to prevent occlusion. After surgery, animals were treated with Pentabiotic (Fort Dodge, 0.3 mL/kg, intramuscular). The experiments were initiated 1 week after surgery.
Drugs and microinjection procedure
The non-selective HO inhibitor zinc deuteroporphyrin 2,4-bis glycol (ZnDPBG, 50 nmol/4 μL and 200 nmol/4 μL) and hemin were obtained from Porphyrin Products (Logan, UT, USA). ZnDPBG was dissolved in 50 mmol/L of Na 2 CO 3 and stored in the dark. Hemin was used to prepare heme-lysinate (at the doses 150 nmol/4 μL, 300 nmol/4 μL and 600 nmol/4 μL), a HO-CO-cGMP pathway inducer, as previously described ). Heme-free preparations were used as amino acid (L-lysine) vehicle control solutions. The vehicle of hemelysinate consisted of L-lysine (14.2 μmol/mL), ethanol (5%), propylene glycol (40%) and sterile water (55%). The sGC inhibitor 1H-[1,2,4] oxadiazolo [4,3-a] quinoxaline-1-one (ODQ, 5.4 nmol/4 μL) was purchased from Tocris Cookson (St. Louis, MO) and dissolved in a vehicle consisting of 1% DMSO in pyrogen-free sterile saline. The doses employed were based on previous studies [Nascimento and Branco, 2008; Ravanelli et al., 2006; . For the i.c.v. injections, a 10-μL Hamilton syringe connected to a dental injection needle by a PE-10 catheter was used. At the time of drug administration, the stylet was replaced with the injection needle and 4 μL of the studied drug were infused over a period of 1 min (Steiner et al., 2003; Paro et al., 2002; Ravanelli et al., 2006) . To prevent reflux, the needle was kept inside the guide cannula for 40 s after the end of the infusion.
Tail flick test
Nociception was assessed with a tail flick apparatus. Rats were restrained manually and placed on the apparatus, which measured time in seconds (latency) that the animal took to issue the reflection, that is, remove the tail from the noxious thermal stimulus. A cutoff time of 6 s was used to prevent tissue damage. Before treatment was initiated, the response latency in seconds for each animal was determined three consecutive times at random intervals of 1-3 min. After measurement of basal latency, animals were divided into different experimental groups and were then subjected to tail flick test after various experimental treatments at intervals of 15 min until the maximum time of 120 min. Rats previously cannulated in the lateral cerebral ventricle after surgery were treated with Pentabiotic. The experiments were initiated 1 week after surgery. The animals were evaluated by the tail flick test to determine the baseline and then microinjected i.c.v. with heme-lysinate (150 nmol/4 μL, 300 nmol/4 μL and 600 nmol/4 μL) or the L-lysine vehicle solution (4 μL). The rats were then submitted 15 min later to the nociceptive test at 15-min intervals until 120 min. In another experimental group, the animals were evaluated by the tail flick test to determine the baseline and then microinjected i.c.v. with ZnDPBG (200 nmol/ 4 μL) and 15 min later, heme-lysinate (150 nmol/4 μL) was injected into the lateral ventricle. The rats were then submitted 15 min later to the nociceptive test at 15-min intervals until 120 min.
4.5.3. Determination of the effect of the intracerebroventricular sGC inhibitor ODQ in acute nociception in rats, as assessed by the tail flick test
Rats previously cannulated in the lateral cerebral ventricle were treated with Pentabiotic. The experiments were initiated 1 week after surgery. The animals were evaluated in the tail flick test to determine the baseline and then microinjected i.c. v. with ODQ (5.2 nmol/4 μL) or with DMSO 1% vehicle (4 μL) 30 min before i.c.v. administration of heme-lysinate (300 nmol/4 μL) or L-lysine vehicle solution (4 μL). Fifteen minutes later, rats were submitted to the nociceptive test again at intervals of fifteen minutes until one hundred twenty minutes.
Histology
At the end of the experiments, rats were anesthetized with hydrate of chloral (10%, 0.35 mL/100 mg body weight, i.p.) and transcardially perfused with saline (NaCl, 0.9%), followed by 10% formalin. The brains were then removed and fixed in 10% formalin. The material was then submitted to routine histological processing and sections were observed under a microscope according to the Paxinos and Watson Atlas (1998) .
Statistical analysis
Each tail flick latency was normalized using an index of antinociception tail flick test (AI) according to the following formula: tail flick test − tail flick control / cutoff time − tail flick control, where tail flick control is the average of 3 baselines of tail-flick latencies. AI represents the antinociception index tail flick test; latency is the time that the animal takes to issue a response after the experimental treatment; baseline is the period of latency in the control; 6 s were necessary to stop the noxious thermal stimulus. The data are reported as the mean AI ± SEM (standard error of mean) and were analyzed by repeated measures multivariate analysis of variance, with the variables being time (repeated factor) and treatment (independent factor), followed by one-way ANOVA and Tukey's test. For the different experimental groups, the values of AI were compared with treatment vs. time using a two-way ANOVA for repeated measures test followed by Student Newman-Keuls. Data were considered statistically significant when p < 0.05.
